Japanese Pharma, Hungry For Global Deals, Can Fill Gap of Shrinking Partners - PharmAsia Summit
This article was originally published in PharmAsia News
Executive Summary
SAN FRANCISCO - The number of large Western pharmaceutical companies is shrinking due to M&A activity, and outward-looking Japanese firms of all sizes are quickly becoming an attractive option for biotechs looking for global and regional deals
You may also be interested in...
Platform Start-Up Anaphore And Mitsubishi Tanabe Ink Deal For Autoimmune Therapies
Anaphore, Inc., a La Jolla, CA, start-up with a novel platform for developing trimeric proteins called Atrimers, has partnered with Mitsubishi Tanabe Pharma Corporation to work on autoimmune diseases
Platform Start-Up Anaphore And Mitsubishi Tanabe Ink Deal For Autoimmune Therapies
Anaphore, Inc., a La Jolla, CA, start-up with a novel platform for developing trimeric proteins called Atrimers, has partnered with Mitsubishi Tanabe Pharma Corporation to work on autoimmune diseases
Platform Start-Up Anaphore And Mitsubishi Tanabe Ink Deal For Autoimmune Therapies
Anaphore's novel Atrimer platform creates trivalent protein drugs to bind all three domains on trivalent ligands and receptors, a presumed advantage over two-armed antibodies.